Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
68 hedge funds and large institutions have $848M invested in Orchard Therapeutics plc American Depositary Shares in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 5 closing their positions.
500% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 5
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
58% more funds holding
Funds holding: 43 → 68 (+25)
3% less capital invested
Capital invested by funds: $875M → $848M (-$27.5M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$35.4M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$29.2M |
| 3 |
DM
Deerfield Management
New York
|
+$15.8M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.2M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management III
New York
|
-$2.37M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.59M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.02M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$1M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$693K |
ORTX Hedge Fund Activity: Q2 2019 in Review
68 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q2 2019, worth a combined $848M — down 3.1% from $875M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ORTX positions and 5 closed out — a net gain of 25 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $35.4M. The largest seller was VHCP Management III, cutting an estimated $2.37M.
- 68 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q2 2019, up from 43 in Q1 2019.
- Funds reported $848M of Orchard Therapeutics plc American Depositary Shares stock for Q2 2019, down 3.1% quarter-over-quarter.
- 30 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q2 2019 and 5 closed out, a net change of +25 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q2 2019 was T. Rowe Price Associates, an estimated $35.4M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q2 2019 was VHCP Management III, an estimated $2.37M sold.
Based on aggregated 13F filings for Q2 2019.